ACM
EVOK

Altium Capital Management’s Evoke Pharma EVOK Stock Holding History

Altium Capital Management’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-57,703
Closed -$366K – 89
2024
Q2 		$366K Sell
57,703
-2,709
-4% -$16.3K 0.15% 42
2024
Q1 		$442K Buy
+60,412
New +$513K 0.18% 45

Other funds holding EVOK

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Altium Capital Management's EVOK Position: Q3 2024 in Review

Altium Capital Management sold out of Evoke Pharma (EVOK) in Q3 2024, closing a stake of 57,703 shares — an estimated $366K sold.

Altium Capital Management first reported a position in EVOK in Q1 2024 and held it in 2 quarters. The position peaked at $442K in Q1 2024. 12 funds tracked by Wall St. Rank hold EVOK as of Q3 2024.

  • Altium Capital Management reported no remaining Evoke Pharma position as of Q3 2024 after selling out during the quarter.
  • Altium Capital Management sold 57,703 Evoke Pharma shares in Q3 2024, an estimated $366K.
  • Altium Capital Management first reported a position in Evoke Pharma in Q1 2024 and held it in 2 quarters.
  • Altium Capital Management's Evoke Pharma position peaked at $442K in Q1 2024.
  • 12 funds tracked by Wall St. Rank held Evoke Pharma as of Q3 2024.

Based on Altium Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.